Product
Ipilimumab
Aliases
Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS734016, BMS-734016, Ipilimumab 200 MG in 40 ML Injection (15 other aliases)
274 clinical trials
4 abstracts
467 indications
Indication
Pancreatic CancerIndication
MelanomaIndication
Adult DiseaseIndication
Advanced Solid TumorIndication
Metastatic MelanomaIndication
Advanced Solid CancersIndication
Renal Cell CarcinomaIndication
lung cancerIndication
Metastatic Uveal Melanoma in the LiverIndication
cancerIndication
Renal CellIndication
Colorectal CancerIndication
Solid TumorIndication
Prostate CancerIndication
Advanced CancerIndication
MetastasisIndication
Pleural mesotheliomaIndication
MSI-HighIndication
Mismatch Repair DeficiencyIndication
Hepatocellular CarcinomaIndication
Renal Cell CancerIndication
Skin CancerIndication
Lung CancerIndication
NSCLCIndication
ALK Gene AberrationsIndication
Colon CancerIndication
Advanced or Metastatic Solid TumorsIndication
Unresectable MelanomaIndication
MesotheliomaIndication
malignantIndication
Mesothelioma, Malignant, PleuralIndication
Peritoneal MesotheliomaIndication
CholangiocarcinomaIndication
Cholangiocarcinoma RecurrentIndication
Ovarian CancerIndication
Non Small Cell Lung Cancer MetastaticIndication
Ovarian Serous AdenocarcinomaIndication
Colorectal cancerIndication
Kidney NeoplasmsIndication
CancerIndication
Uveal MelanomaIndication
Broad Solid TumorIndication
Bladder CancerIndication
Head and Neck Squamous Cell CarcinomaIndication
Solid TumorsIndication
Advanced MalignanciesIndication
Metastatic CancerIndication
Stage IV melanomaIndication
AdultIndication
Stomach CancerIndication
Head and Neck CancerIndication
TumorIndication
Pan-TumorIndication
Endometrial CancerIndication
Endometrial Cancer RecurrentIndication
Lung Cancer RecurrentIndication
Non-small Cell Lung Cancer MetastaticIndication
Non-small Cell CarcinomaIndication
Breast CancerIndication
Non-small Cell Lung CarcinomaIndication
Uveal melanomaIndication
Liver MetastasesIndication
Non-Small-Cell Lung CarcinomaIndication
Non-Small Cell LungIndication
Healthy Male VolunteersIndication
Non-Hodgkin lymphomaIndication
Hodgkin lymphomaIndication
Multiple MyelomaIndication
Healthy SubjectsIndication
Undifferentiated Pleomorphic SarcomaIndication
MyxofibrosarcomaIndication
Clear-Cell Renal Cell CarcinomaIndication
GlioblastomaIndication
Esophageal CancerIndication
Esophageal adenocarcinomaIndication
Acute Myeloid LeukemiaIndication
Myelodysplastic SyndromesIndication
Myeloproliferative NeoplasmsIndication
Chronic Myelomonocytic LeukemiaIndication
MyelofibrosisIndication
Stage IIIIndication
Stage IVIndication
Stage III MelanomaIndication
Stage IIIA Skin MelanomaIndication
Stage IIIB skin melanomaIndication
Stage IIIC Skin MelanomaIndication
Skin MelanomaIndication
melanomaIndication
Papillary Renal Cell CarcinomaIndication
Chromophobe Renal Cell CarcinomaIndication
Collecting Duct Renal Cell CarcinomaIndication
Advanced Renal Cell CarcinomaIndication
Metastatic NCC Renal Cell CarcinomaIndication
Mucosal melanomaIndication
Ocular melanomaIndication
Acral Lentiginous MelanomaIndication
Cutaneous MelanomaIndication
Uveal Melanoma (Stage IIIC, AJCC v7)Indication
Stage IV Cutaneous MelanomaIndication
B-cell LymphomaIndication
Chronic Lymphocytic LeukemiaIndication
Acute Lymphocytic LeukemiaIndication
small cell lung cancerIndication
Neuroendocrine TumorsIndication
Carcinoid TumorIndication
Metastatic Malignant Solid NeoplasmIndication
Recurrent Malignant Solid NeoplasmIndication
Platinum-Resistant Ovarian CarcinomaIndication
Clear Cell Renal Cell CarcinomaIndication
Stage III Renal Cell Cancer AJCC v8Indication
Stage IV Renal Cell Cancer AJCC v8Indication
Salivary Gland CarcinomaIndication
Recurrent Salivary Gland CarcinomaIndication
Stage IVA Major Salivary Gland CarcinomaIndication
Major Salivary Gland CarcinomaIndication
Stage IVC Major Salivary Gland CarcinomaIndication
LeiomyosarcomaIndication
Uterine Corpus LeiomyosarcomaIndication
Small Cell Lung CancerIndication
Colon AdenocarcinomaIndication
Rectal AdenocarcinomaIndication
Stage III Colon CancerIndication
Rectal cancerIndication
Colon Cancer, Stage IIIA AJCC v8Indication
Rectal CancerIndication
Colon Cancer (Stage IIIB)Indication
Colorectal Cancer stage IV AJCC v8Indication
Stage IV Rectal CancerIndication
Colon Cancer, Stage IVA (AJCC v8)Indication
Stage IVA Colorectal Cancer AJCC v8Indication
Stage IVA Rectal Cancer (AJCC v8)Indication
Stage IVB Colon CancerIndication
Stage IVB Colorectal Cancer AJCC v8Indication
Stage IVB Rectal Cancer AJCC v8Indication
Stage IVC Colorectal Cancer AJCC v8Indication
Extensive-stage Small Cell Lung CancerIndication
Stage IVB Uterine Corpus Cancer AJCC v8Indication
Melanoma of Unknown PrimaryIndication
Merkel Cell CarcinomaIndication
Malignant Melanoma Stage IIIIndication
Soft Tissue SarcomaIndication
Melanoma Stage IVIndication
Stage IV Cutaneous Merkel Cell CarcinomaIndication
Basal Cell CarcinomaIndication
Skin Metastatic CarcinomaIndication
Squamous Cell CarcinomaIndication
Skin Squamous Cell CarcinomaIndication
Dedifferentiated LiposarcomaIndication
Recurrent Dedifferentiated LiposarcomaIndication
Gastrointestinal CancerIndication
Non-Small CellIndication
Malignant NeoplasmIndication
KITIndication
Gastrointestinal stromal tumorIndication
NeoplasmIndication
Esophageal Adenocarcinoma AJCC v8Indication
Gastroesophageal Junction AdenocarcinomaIndication
Esophageal AdenocarcinomaIndication
Kidney Medullary CarcinomaIndication
INI 1 Protein ExpressionIndication
Genital NeoplasmsIndication
maleIndication
Urogenital NeoplasmsIndication
Neoplasms by SiteIndication
Prostate DiseaseIndication
Anal Canal Squamous Cell CarcinomaIndication
Anal Canal CarcinomaIndication
Anal Canal CancerIndication
Stage II Breast CancerIndication
Stage IIB Breast CancerIndication
Breast Cancer, Stage IVIndication
Triple-Negative Breast CarcinomaIndication
Breast Cancer AJCC Stage IAIndication
Stage IIA Breast CancerIndication
Stage IIIA Breast CancerIndication
Stage IIIB Breast CancerIndication
Stage IV Breast Cancer AJCC v8Indication
Endometrial Clear Cell AdenocarcinomaIndication
Endometrial Dedifferentiated CarcinomaIndication
Endometrial Endometrioid AdenocarcinomaIndication
Endometrial Mixed Cell AdenocarcinomaIndication
Endometrial Mucinous AdenocarcinomaIndication
Endometrial CarcinomaIndication
Endometrioid AdenocarcinomaIndication
Biliary Tract CancerIndication
female reproductive system neoplasmIndication
MSI-H Solid Malignant TumorIndication
Malignant Solid NeoplasmIndication
NeuroblastomaIndication
Pediatric Solid TumorIndication
Stage III Cutaneous Melanoma AJCC v7Indication
Stage IIIA Cutaneous Melanoma AJCC v7Indication
High Grade Serous OvarianIndication
fallopian tubeIndication
Primary Peritoneal CancerIndication
Neuroendocrine CarcinomaIndication
Bone MetastasisIndication
Major Salivary Gland CancerIndication
Acute bilineal leukemiaIndication
Acute Biphenotypic LeukemiaIndication
Brain MetastasisIndication
Bone SarcomaIndication
Dedifferentiated ChondrosarcomaIndication
Giant Cell Tumor of BoneIndication
Ovarian CarcinosarcomaIndication
Thyroid CarcinomaIndication
OsteosarcomaIndication
Myelodysplastic SyndromeIndication
Recurrent Acute Myeloid LeukemiaIndication
Therapy-Related Acute Myeloid LeukemiaIndication
Malignant Rhabdoid TumorIndication
Rhabdoid Tumor of the KidneyIndication
Epithelioid SarcomaIndication
Atypical Teratoid/Rhabdoid TumorIndication
INI1 Negative TumorsIndication
SMARCA4-deficient Malignant TumorsIndication
Sarcomatoid Renal Cell CarcinomaIndication
Hematopoietic and Lymphoid Cell NeoplasmIndication
Small Lymphocytic LymphomaIndication
Refractory Chronic Lymphocytic LeukemiaIndication
Richter syndromeIndication
Stage IIIC Cutaneous Melanoma AJCC v8Indication
Stage IIID Cutaneous Melanoma AJCC v8Indication
Adenocarcinoma of the LungIndication
Non-Small Cell Lung CarcinomaIndication
Stage IV Lung CancerIndication
Recurrent Ovarian CarcinomaIndication
Anaplastic Thyroid CarcinomaIndication
Thyroid Gland Squamous Cell CarcinomaIndication
Triple-Negative Breast CancerIndication
Melanoma Brain MetastasesIndication
Localized Oesogastric AdenocarcimonaIndication
MSI and or dMMRIndication
Bladder Squamous Cell CarcinomaIndication
Bladder Urothelial CarcinomaIndication
Sarcomatoid Urothelial CarcinomaIndication
Malignant Genitourinary System NeoplasmIndication
Penile CancerIndication
Penile Squamous Cell CarcinomaIndication
Renal Pelvis Urothelial CarcinomaIndication
Bladder Cancer Stage III AJCC v8Indication
Stage III Renal Pelvis CancerIndication
Ureter Cancer AJCC v8Indication
Urethral Cancer AJCC v8Indication
Stage IV Bladder CancerIndication
Stage IV Ureter Cancer AJCC v8Indication
Urethral CancerIndication
Ureter Urothelial CarcinomaIndication
Urethral Urothelial CarcinomaIndication
Cervical CancerIndication
Head and Neck CancersIndication
Metastatic Renal Cell CarcinomaIndication
Metastatic renal cell carcinomaIndication
Bladder AdenocarcinomaIndication
Clear Cell Adenocarcinoma of the BladderIndication
Bladder mixed adenocarcinomaIndication
Neuroendocrine Bladder CarcinomaIndication
Collecting Duct CarcinomaIndication
Giant Cell Urothelial CarcinomaIndication
Bladder lymphoepithelioma-like carcinomaIndication
Nested Urothelial CarcinomaIndication
Large Cell Neuroendocrine CarcinomaIndication
Malignant Testicular Leydig Cell TumorIndication
Testicular Sertoli Cell TumorIndication
Bladder Giant Cell Urothelial CarcinomaIndication
Lipid-Rich Urothelial CarcinomaIndication
Bladder Sarcomatoid Urothelial CarcinomaIndication
Squamous Cell Carcinoma of the BladderIndication
Metastatic kidney medullary carcinomaIndication
penile cancerIndication
Urethral CarcinomaIndication
Urachal AdenocarcinomaIndication
Urethral clear cell adenocarcinomaIndication
Metastatic Biliary Tract CancerIndication
Anal CancerIndication
HIV InfectionIndication
Kaposi SarcomaIndication
Hodgkin LymphomaIndication
Peritoneal NeoplasmIndication
Malignant Retroperitoneal NeoplasmIndication
Fallopian Tube CarcinomaIndication
Primary Peritoneal CarcinomaIndication
Peritoneal CarcinomatosisIndication
Platinum-Refractory Ovarian CarcinomaIndication
Recurrent Cervical CarcinomaIndication
Recurrent Fallopian Tube CarcinomaIndication
Recurrent Primary Peritoneal CarcinomaIndication
Fallopian Tube Cancer, Stage IV, AJCC v8Indication
Stage IV Ovarian CancerIndication
Primary Peritoneal Cancer (Stage IV)Indication
Stage IV Fallopian Tube Cancer AJCC v8Indication
Stage IV Ovarian Cancer AJCC v8Indication
Stage IVB Cervical Cancer AJCC v8Indication
Fallopian Tube CancerIndication
Ovarian Cancer Stage IVB AJCC v8Indication
Brain MetastasesIndication
Liver MetastasisIndication
Borderline ResectableIndication
Nasopharyngeal CarcinomaIndication
Colon Carcinoma with Liver MetastasisIndication
Colorectal AdenocarcinomaIndication
Pancreatic adenocarcinomaIndication
Pancreatic Cancer, Stage IIIndication
Stage IIB Pancreatic CancerIndication
Stage III Pancreatic CancerIndication
Colorectal Cancer, Stage IVBIndication
Non-Hodgkin LymphomaIndication
RhabdomyosarcomaIndication
Hodgkin's LymphomaIndication
Refractory Non-Hodgkin LymphomaIndication
Fibrolamellar Hepatocellular CarcinomaIndication
Gastrointestinal Stromal TumorIndication
Ewing SarcomaIndication
hepatoblastomaIndication
Wilms tumorIndication
Genitourinary CancerIndication
Adrenocortical CancerIndication
Upper Tract Urothelial CarcinomaIndication
Refractory Germ-cellIndication
Advanced Soft Tissue SarcomaIndication
LiposarcomaIndication
Metastatic Unresectable SarcomaIndication
Pleomorphic LiposarcomaIndication
Soft Tissue Sarcoma AJCC v7Indication
Bone Sarcoma AJCC v7Indication
Stage IV Soft Tissue Sarcoma AJCC v7Indication
Stage IVB Bone Sarcoma AJCC v7Indication
Advanced Nonsmall Cell Lung CancerIndication
GEP-NETIndication
Grade 2 meningiomaIndication
Grade 3 MeningiomaIndication
MeningiomaIndication
Melanoma stage IIIIndication
Metastatic Mucosal MelanomaIndication
Ocular MelanomaIndication
Recurrent B Acute Lymphoblastic LeukemiaIndication
Recurrent Mixed Phenotype Acute LeukemiaIndication
Mixed Phenotype Acute LeukemiaIndication
Hodgkin's lymphomaIndication
Breast NeoplasmsIndication
Inoperable DiseaseIndication
lymphomaIndication
Glioblastoma MultiformeIndication
Grade IV AstrocytomaIndication
Metastatic Neuroendocrine CarcinomaIndication
Metastatic Neuroendocrine NeoplasmIndication
Small Cell Neuroendocrine CarcinomaIndication
ImmunotherapyIndication
Head and Neck NeoplasmsIndication
BCLC Stage B Hepatocellular CarcinomaIndication
BCLC Stage C Hepatocellular CarcinomaIndication
Stage IIIA Hepatocellular CarcinomaIndication
Nasal Type Extranodal NK/T-cell LymphomaIndication
Anaplastic Large Cell LymphomaIndication
Angioimmunoblastic T-cell LymphomaIndication
Cutaneous B-cell Non-Hodgkin LymphomaIndication
Hepatosplenic T-cell LymphomaIndication
Intraocular lymphomaIndication
Nodal Marginal Zone B-cell LymphomaIndication
Peripheral T-cell LymphomaIndication
Burkitt lymphomaIndication
Adult Lymphomatoid GranulomatosisIndication
Adult Immunoblastic Large Cell LymphomaIndication
Adult Lymphoblastic LymphomaIndication
Adult T-cell Leukemia/LymphomaIndication
Cutaneous T-cell Non-Hodgkin LymphomaIndication
Follicular LymphomaIndication
Grade 2 Follicular LymphomaIndication
Grade 3 Follicular LymphomaIndication
Mantle Cell LymphomaIndication
Marginal Zone LymphomaIndication
Mycosis Fungoides/Sezary SyndromeIndication
Recurrent Rectal CancerIndication
Hairy Cell LeukemiaIndication
Lymphoma of the Small IntestineIndication
splenic marginal zone lymphomaIndication
Testicular LymphomaIndication
Waldenström MacroglobulinemiaIndication
Cutaneous Melanoma AJCC v8Indication
Cutaneous Melanoma (Clinical Stage IB)Indication
Castration Levels of TestosteroneIndication
Castration-Resistant Prostate CarcinomaIndication
prostate-specific antigen progressionIndication
Prostate AdenocarcinomaIndication
Metastatic Carcinoma in the LungIndication
Resectable Hepatocellular CarcinomaIndication
Metastatic Urothelial CarcinomaIndication
Nerve Sheath TumorsIndication
fallopian tube carcinomaIndication
Metastatic Lung Non-Small Cell CarcinomaIndication
Stage III Lung Cancer AJCC v8Indication
Stage IIIA Lung CancerIndication
Stage IIIB Lung CancerIndication
Lung Cancer Stage IVA AJCC v8Indication
Hypopharyngeal Squamous Cell CarcinomaIndication
Laryngeal Squamous Cell CarcinomaIndication
Oropharyngeal Squamous Cell CarcinomaIndication
Colorectal NeoplasmsIndication
GliosarcomaIndication
Malignant GliomaClinical trial
A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma (REVOLUTION)Status: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
A Phase 1/2 Study of ANV419 as Monotherapy or in Combination With Anti-PD-1 or Anti-CTLA-4 Antibody Following Anti-PD-1/Anti-PD-L1 Antibody Treatment in Patients With Unresectable or Metastatic Cutaneous Melanoma (OMNIA-1)Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)Status: Active (not recruiting), Estimated PCD: 2024-08-29
Clinical trial
A Phase I Study of BMS-986301 Monotherapy and Combination Therapy With Nivolumab and Ipilimumab in Participants With Advanced Solid CancersStatus: Active (not recruiting), Estimated PCD: 2024-04-19
Clinical trial
A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of RelapseStatus: Completed, Estimated PCD: 2023-09-12
Clinical trial
ANV419 First in Human Study Phase 1: Open-label, Dose Escalation Study of ANV419 as Single Agent and in Combination With Ipilimumab in Patients With Relapsed/Refractory Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy for Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk FactorsStatus: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A Phase 1/1b, Open-Label Study of the Pressure-Enabled Hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination With Intravenous Checkpoint Blockade in Adults With Metastatic Uveal MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Phase 1, Multicenter, Open-Label Study of SQZ-AAC-HPV as Monotherapy and in Combination With Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid TumorsStatus: Terminated, Estimated PCD: 2023-11-02
Clinical trial
A Phase 2 Randomized Study of BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung CancerStatus: Completed, Estimated PCD: 2022-12-27
Clinical trial
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2027-03-01
Clinical trial
A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and Non-MSI-H Colon CancerStatus: Active (not recruiting), Estimated PCD: 2024-02-16
Clinical trial
A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2022-04-05
Clinical trial
A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Anti-PD-1-Resistant Locally Advanced or Metastatic CancersStatus: Not yet recruiting, Estimated PCD: 2027-12-31
Clinical trial
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2019-02-05
Clinical trial
An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic MelanomaStatus: Completed, Estimated PCD: 2018-05-09
Clinical trial
A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Advanced Hepatocellular Carcinoma Subjects With or Without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects Who Are Naive to Systemic TherapyStatus: Active (not recruiting), Estimated PCD: 2024-06-28
Clinical trial
A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing CancerStatus: Active (not recruiting), Estimated PCD: 2028-11-02
Clinical trial
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2016-08-01
Clinical trial
A Phase 1/2 Study of Nivolumab (BMS-936558) in Combination With Ipilimumab (BMS-734016) in Chinese Participants With Previously Treated Metastatic or Recurrent Solid TumorsStatus: Completed, Estimated PCD: 2024-01-05
Clinical trial
A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal CancersStatus: Active (not recruiting), Estimated PCD: 2024-03-11
Clinical trial
A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2019-08-16
Clinical trial
A Phase 1b/2 Pressure Enabled Regional Immuno-Oncology Study of Hepatic Arterial Infusion of SD-101 With Systemic Checkpoint Blockade for Hepatocellular Carcinoma and Intrahepatic CholangiocarcinomaStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence (CheckMate 238: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 238)Status: Active (not recruiting), Estimated PCD: 2018-11-26
Clinical trial
A Phase II, Randomized, Open-label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First-line Therapy for Unresectable Pleural Mesothelioma in Chinese ParticipantsStatus: Recruiting, Estimated PCD: 2026-10-07
Clinical trial
A Phase 4 Study of Nivolumab in Combination With Ipilimumab in Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate-or Poor-risk Factors Conducted in IndiaStatus: Completed, Estimated PCD: 2024-01-04
Clinical trial
A Phase 1/2 Study of BMS-986408 Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Participants With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2025-10-14
Clinical trial
A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced CancersStatus: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A Phase 1/2, Safety Lead-in and Dose Expansion, Open-label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination With Nivolumab and Ipilimumab in Previously Treated Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 MutationStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)Status: Recruiting, Estimated PCD: 2027-01-15
Clinical trial
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2020-02-12
Clinical trial
A Study of the Safety and Efficacy of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Patients With Advanced MelanomaStatus: Completed, Estimated PCD: 2021-12-02
Clinical trial
An Exploratory Study of the Biologic Effects of Nivolumab and Ipilimumab Monotherapy and Nivolumab in Combination With Ipilimumab Treatment in Subjects With Advanced Melanoma (Unresectable or Metastatic)Status: Completed, Estimated PCD: 2017-09-12
Clinical trial
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)Status: Completed, Estimated PCD: 2023-09-22
Clinical trial
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid TumorsStatus: Recruiting, Estimated PCD: 2029-08-09
Clinical trial
Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid TumorsStatus: Completed, Estimated PCD: 2024-01-25
Clinical trial
Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIB-IV MelanomaStatus: Completed, Estimated PCD: 2016-08-23
Clinical trial
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
Efficacy and Safety of UV1 Vaccination in Combination With Nivolumab and Ipilimumab as First Line Treatment of Patients With Unresectable or Metastatic Melanoma (INITIUM Study)Status: Completed, Estimated PCD: 2024-01-11
Clinical trial
A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid MalignanciesStatus: Active (not recruiting), Estimated PCD: 2025-04-19
Clinical trial
A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial CancerStatus: Active (not recruiting), Estimated PCD: 2024-10-30
Clinical trial
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer TherapiesStatus: Recruiting, Estimated PCD: 2029-08-25
Clinical trial
A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant TumorsStatus: Active (not recruiting), Estimated PCD: 2024-04-22
Clinical trial
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)Status: Completed, Estimated PCD: 2022-05-11
Clinical trial
Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone and in Combination With Nivolumab, Ipilimumab, or Pembrolizumab in Adult Subjects With Advanced and/or Refractory Solid Tumor MalignanciesStatus: Completed, Estimated PCD: 2020-07-01
Clinical trial
A Phase 2b Study of Immune Checkpoint Inhibition With or Without Dorgenmeltucel-L (HyperAcute Melanoma) Immunotherapy for Stage IV Melanoma PatientsStatus: Terminated, Estimated PCD: 2018-04-05
Clinical trial
ADaptiVe Biomarker Trial That InformS Evolution of TherapyStatus: Completed, Estimated PCD: 2021-03-31
Clinical trial
A Randomized, Open-Label, Phase 2 Study of a Patient-Specific Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer With Minimal Residual Disease Following Surgical Resection and Standard Adjuvant ChemotherapyStatus: Terminated, Estimated PCD: 2022-09-01
Clinical trial
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination With Immune Therapies in Subjects With Advanced or Metastatic MalignanciesStatus: Completed, Estimated PCD: 2019-09-17
Clinical trial
A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)Status: Completed, Estimated PCD: 2021-11-23
Clinical trial
Sargramostim Safety and Tolerability With Standard Of Care Ipilimumab Containing Therapy in Patients With Solid TumorsStatus: Withdrawn, Estimated PCD: 2025-09-01
Clinical trial
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic MalignanciesStatus: Completed, Estimated PCD: 2021-11-09
Clinical trial
A Phase 2, Single-arm Open-label Study of Combination Nivolumab and Ipilimumab Retreatment in Advanced Renal Cell Carcinoma Patients Progressing on Nivolumab Maintenance Therapy After Nivolumab and Ipilimumab InductionStatus: Terminated, Estimated PCD: 2021-11-15
Clinical trial
An Open-label, Multi-center, Rollover Study in Subjects With Advanced Solid Tumor Malignancies After Participation in a Vopratelimab (JTX-2011) Clinical StudyStatus: Completed, Estimated PCD: 2023-01-31
Clinical trial
An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in Combination With Ipilimumab in Subjects With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)Status: Completed, Estimated PCD: 2022-02-17
Clinical trial
A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural MesotheliomaStatus: Completed, Estimated PCD: 2020-03-25
Clinical trial
A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 451)Status: Completed, Estimated PCD: 2018-10-01
Clinical trial
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-09-19
Clinical trial
A Study of Nivolumab in Combination With Ipilimumab (Part 1); and Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)Status: Completed, Estimated PCD: 2018-06-22
Clinical trial
A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)Status: Completed, Estimated PCD: 2019-01-23
Clinical trial
A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2021-12-20
Clinical trial
A Phase 1 Multi-Targeted Study to Promote Anti-Tumor Immunity in ER Positive, HER2 Negative Advanced Breast CancerStatus: Completed, Estimated PCD: 2022-08-15
Clinical trial
A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid TumorsStatus: Completed, Estimated PCD: 2019-12-13
Clinical trial
A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination With Ipilimumab or Ipilimumab Alone in Participants With Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 TherapyStatus: Completed, Estimated PCD: 2023-07-26
Clinical trial
Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920)Status: Completed, Estimated PCD: 2020-05-11
Clinical trial
A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced MalignanciesStatus: Completed, Estimated PCD: 2021-06-01
Clinical trial
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients With Advanced Solid Malignancies and Expansion in Select MalignanciesStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)Status: Completed, Estimated PCD: 2022-05-03
Clinical trial
A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant TumorsStatus: Completed, Estimated PCD: 2021-10-26
Clinical trial
Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects With Virus-Positive and Virus-Negative Solid TumorsStatus: Completed, Estimated PCD: 2021-03-19
Clinical trial
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2023-02-09
Clinical trial
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC ParticipantsStatus: Recruiting, Estimated PCD: 2025-07-08
Clinical trial
A Phase I/II Study of MK-3475 (SCH900475) in Combination With Chemotherapy or Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CarcinomaStatus: Completed, Estimated PCD: 2016-11-07
Clinical trial
Randomized, OpenLabel, Phase 3 Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLCStatus: Active (not recruiting), Estimated PCD: 2021-09-08
Clinical trial
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor RiskStatus: Active (not recruiting), Estimated PCD: 2022-01-31
Clinical trial
Open-Label, Randomized Trial of Nivolumab (BMS-936558) Plus Pemetrexed/Platinum or Nivolumab Plus Ipilimumab (BMS-734016) vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor TherapyStatus: Completed, Estimated PCD: 2022-01-20
Clinical trial
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic MelanomaStatus: Terminated, Estimated PCD: 2015-07-01
Clinical trial
An Open-Label Phase 1b Clinical Study of Intravenous CAVATAK® (Coxsackievirus A21, CVA21), in Combination With Ipilimumab in Subjects With Uveal Melanoma Metastatic to Liver (VLA-024 CLEVER)Status: Completed, Estimated PCD: 2019-05-22
Clinical trial
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598)Status: Completed, Estimated PCD: 2020-09-01
Clinical trial
A Randomized, Intravenous Single-Dose, Parallel, Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX13 and YERVOY® (US-, EU-, and CN-Sourced) in Healthy Chinese Male SubjectsStatus: Recruiting, Estimated PCD: 2024-05-28
Clinical trial
An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)Status: Completed, Estimated PCD: 2021-05-10
Clinical trial
Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic MalignanciesStatus: Active (not recruiting), Estimated PCD: 2020-09-25
Clinical trial
Compare the Pharmacokinetics, Safety, Tolerance and Immunogenicity of Single Doses of IBI310 and Ipilimumab in Healthy Male Subjects: a Randomized Double-blind Parallel Controlled Phase I Clinical StudyStatus: Active (not recruiting), Estimated PCD: 2022-09-27
Clinical trial
Phase 2 Study of FLX475 in Combination With Ipilimumab in Advanced MelanomaStatus: Terminated, Estimated PCD: 2022-09-13
Clinical trial
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)Status: Terminated, Estimated PCD: 2021-06-01
Clinical trial
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2017-06-26
Clinical trial
ENVASARC: A Pivotal Trial Of Envafolimab, And Envafolimab In Combination With Ipilimumab, In Patients With Advanced Or Metastatic Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Who Have Progressed On Prior ChemotherapyStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 1/1b Study of Sitravatinib in Combination With Nivolumab and Ipilimumab in Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid MalignanciesStatus: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
A PHASE 1b STUDY OF INTRATUMORAL CAVATAK® (COXSACKIEVIRUS A21, CVA21) AND IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA (VLA-013 MITCI)Status: Completed, Estimated PCD: 2019-11-05
Clinical trial
A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of GlioblastomaStatus: Active (not recruiting), Estimated PCD: 2019-06-17
Clinical trial
A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction CancerStatus: Active (not recruiting), Estimated PCD: 2020-05-27
Clinical trial
A Randomized Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Subjects With Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2021-01-18
Clinical trial
A Pilot Trial of Ipilimumab With Nivolumab for Participants With Resected Stages IIIB/IIIC/ IV MelanomaStatus: Completed, Estimated PCD: 2018-11-01
Clinical trial
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.Status: Active (not recruiting), Estimated PCD: 2022-10-14
Clinical trial
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCTStatus: Active (not recruiting), Estimated PCD: 2024-05-24
Clinical trial
A Randomized Phase 2 Study of Rituxan Hycela in Patients With Advanced Melanoma Undergoing Combination Immune Checkpoint Blockade With Nivolumab and IpilimumabStatus: Active (not recruiting), Estimated PCD: 2024-09-13
Clinical trial
A Phase 2 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Advanced Non-Clear Cell Renal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2024-12-20
Clinical trial
A Phase II Prospective, Open-label Trial of Perioperative Combination Nivolumab and Ipilimumab in Patients With Resectable Malignant Peritoneal MesotheliomaStatus: Completed, Estimated PCD: 2023-04-13
Clinical trial
Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV MelanomaStatus: Completed, Estimated PCD: 2023-01-26
Clinical trial
Phase I Study Of CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, Acute Lymphocytic Leukemia, and Chronic Lymphocytic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2014-07-01
Clinical trial
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium. BTCRC-LUN17-127Status: Active (not recruiting), Estimated PCD: 2023-09-25
Clinical trial
An Open-Label, Single Arm Phase II Study of Nivolumab in Combination With Ipilimumab in Subjects With Advanced Neuroendocrine TumorsStatus: Terminated, Estimated PCD: 2021-11-24
Clinical trial
Phase I/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694 With PD-1 Inhibitor, Nivolumab With or Without CTLA-4 Inhibitor, Ipilimumab in Solid TumorsStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Optimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic CancerStatus: Recruiting, Estimated PCD: 2025-08-08
Clinical trial
Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma of All Anatomic Sites of Origin and Non-adenoid Cystic Carcinoma Malignant Tumors of the Salivary GlandStatus: Active (not recruiting), Estimated PCD: 2021-02-24
Clinical trial
Consolidative Ipilimumab and Nivolumab With Thoracic Radiotherapy After Platinum Based Chemotherapy for Patients With Extensive-Stage Small Cell Lung CancerStatus: Completed, Estimated PCD: 2018-10-26
Clinical trial
A Phase 2 Study of Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the UterusStatus: Active (not recruiting), Estimated PCD: 2018-09-20
Clinical trial
Activity and Enhancement of Immune Checkpoint Inhibition With Lurbinectedin in Relapsed/Recurrent Small Cell Lung Cancer (SCLC)Status: Terminated, Estimated PCD: 2023-03-24
Clinical trial
A Phase I Clinical Trial of Regorafenib, Nivolumab, and Ipilimumab in Advanced Chemotherapy Resistant Metastatic MSS Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk MelanomaStatus: Active (not recruiting), Estimated PCD: 2019-02-15
Clinical trial
Randomized, Multi-Institutional Pilot Study of Nivolumab and Radiation Therapy Versus Nivolumab and Ipilimumab as Adjuvant Therapy for Merkel Cell CarcinomaStatus: Completed, Estimated PCD: 2022-12-02
Clinical trial
Phase II Study of Ipilimumab Plus Temozolomide in Patients With Metastatic MelanomaStatus: Completed, Estimated PCD: 2016-08-01
Clinical trial
Multicenter Phase 2 Study to Identify of the Optimal Neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)Status: Active (not recruiting), Estimated PCD: 2020-01-03
Clinical trial
Phase I Study of Single-agent and Combined Checkpoint Inhibition After Allogeneic Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant RecurrenceStatus: Terminated, Estimated PCD: 2023-12-21
Clinical trial
A Phase II Study of the Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV MelanomaStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (Amended Protocol of: Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL)Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 MutationsStatus: Active (not recruiting), Estimated PCD: 2022-12-22
Clinical trial
A Randomized Phase II Trial of Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue SarcomaStatus: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Phase II, Open Label, Randomised, Controlled Trial of Ipilimumab and Nivolumab With Concurrent Intracranial Stereotactic Radiotherapy Versus Ipilimumab and Nivolumab Alone in Patients With Melanoma Brain Metastases.Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase 1/2 Study of Nivolumab and Ipilimumab in Combination With Sirolimus and Prednisone in Kidney Transplant Recipients With Selected Unresectable or Metastatic Cutaneous CancersStatus: Recruiting, Estimated PCD: 2027-01-31
Clinical trial
Phase II Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated LiposarcomaStatus: Active (not recruiting), Estimated PCD: 2025-10-31
Clinical trial
Pre-operative Phase II Trial for Breast Cancer With Nivolumab in Combination With Novel IO (BELLINI Trial)Status: Recruiting, Estimated PCD: 2031-01-01
Clinical trial
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-11-28
Clinical trial
A Phase Ib Study of Neoantigen Vaccine (NeoVax Plus Montanide) in Combination With Nivolumab and Locally Administered Ipilimumab in Patients With Advanced MelanomaStatus: Active (not recruiting), Estimated PCD: 2022-12-27
Clinical trial
A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients With Advanced MalignanciesStatus: Completed, Estimated PCD: 2022-12-13
Clinical trial
A Phase 2 Study of Palliative Radiation and Combination Sequential Immunotherapy for Metastatic Cutaneous Melanoma and Ocular MelanomaStatus: Completed, Estimated PCD: 2021-05-04
Clinical trial
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction AdenocarcinomaStatus: , Estimated PCD: 2026-01-31
Clinical trial
LIMIT Melanoma: (Lysosomal Inhibition + Melanoma ImmunoTherapy) A Phase 1/2 Open Label Trial of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Patients With Advanced MelanomaStatus: Recruiting, Estimated PCD: 2025-10-30
Clinical trial
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary CarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-07-31
Clinical trial
Phase II Study of Radionuclide 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With MetastaticCastration Resistant Prostate Cancer (mCRPC)Status: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
Phase 1 Study of the Administration of Ipilimumab Intra-Lymphatically Using the Sofusa® DoseConnect™ DEVICE With Nivolumab Administered IV in Patients With Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV MelanomaStatus: Active (not recruiting), Estimated PCD: 2023-07-01
Clinical trial
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal CanalStatus: Active (not recruiting), Estimated PCD: 2025-02-15
Clinical trial
SCANDIUM II Trial - A Phase I Randomized Controlled Multicentre Trial of Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma MetastasesStatus: Active (not recruiting), Estimated PCD: 2024-08-04
Clinical trial
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Triple Negative Breast Cancer (TNBC)Status: Not yet recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial CarcinomaStatus: Recruiting, Estimated PCD: 2026-04-30
Clinical trial
A Phase 1 Trial of CTLA-4 Inhibition, With or Without Cetuximab, and in Combination With Memory-like Natural Killer (NK) Cell Immune Cell Therapy in Advanced Head & Neck CancerStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Ipilimumab and Nivolumab Combination Therapy in Patients With Selected Immunotherapy Sensitive Advanced Rare CancersStatus: Active (not recruiting), Estimated PCD: 2026-03-01
Clinical trial
Phase II Multicenter Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2020-09-21
Clinical trial
A Phase II Study of Ipilimumab PLUS Androgen Depravation Therapy in Castrate Sensitive Prostate CarcinomaStatus: Terminated, Estimated PCD: 2017-04-07
Clinical trial
A Single-arm Phase II Trial of Intermittent Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic TherapyStatus: Completed, Estimated PCD: 2023-10-24
Clinical trial
A Multicenter Phase II Randomized Trial Of Immunotherapy Versus Chemotherapy Guided By Circulating Tumor DNA-Based Molecular Response On Patients With Metastatic NSCLCStatus: Recruiting, Estimated PCD: 2026-04-28
Clinical trial
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2021-04-22
Clinical trial
A Phase 1 Study of Combination Nivolumab and Ipilimumab With Irradiated GM-CSF Secreting Autologous Neuroblastoma Cell Vaccine (GVAX) for Relapsed or Refractory NeuroblastomaStatus: Active (not recruiting), Estimated PCD: 2027-01-01
Clinical trial
Integrated Pilot Biomarker Trial of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck CancerStatus: Recruiting, Estimated PCD: 2024-07-26
Clinical trial
Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081Status: Active (not recruiting), Estimated PCD: 2024-02-06
Clinical trial
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced MelanomaStatus: Active (not recruiting), Estimated PCD: 2013-02-15
Clinical trial
A Pilot Study of Nivolumab With or Without Ipilimumab in Combination With Front-Line Neoadjuvant Dose Dense Paclitaxel and Carboplatin Chemotherapy and Post-Surgical Dose Dense Paclitaxel and Carboplatin Chemotherapy in Patients With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
A GCO Trial Exploring the Efficacy and Safety of Nivolumab Monotherapy or Nivolumab Plus Ipilimumab in Pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)Status: Active (not recruiting), Estimated PCD: 2021-07-09
Clinical trial
Dual Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Salivary Gland CancersStatus: Completed, Estimated PCD: 2022-11-05
Clinical trial
An Open-Label Phase II Study of Nivolumab (BMS-936558) in Combination With 5-Azacytidine (Vidaza) or Nivolumab With Ipilimumab in Combination With 5-Azacytidine for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older AML (> 65 Years) PatientsStatus: Completed, Estimated PCD: 2023-10-09
Clinical trial
A Randomized, Pilot Study to Evaluate the Molecular and Cellular Response to Treatment With Nivolumab With Either Adjuvant Ipilimumab or Relatlimab in Adult Patients With Surgically Resectable Melanoma Brain MetastasesStatus: Active (not recruiting), Estimated PCD: 2027-01-01
Clinical trial
Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor TypesStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Phase II Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Advanced Melanoma Receiving Post-progression Dual Immune Checkpoint Inhibitor TherapyStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Neoadjuvant CHemoradiotherapy With Sequential Ipilimumab and NivOlumab in RECtal Cancer (CHINOREC): a Prospective Randomized, Open-label, Multicenter, Phase II Clinical TrialStatus: Completed, Estimated PCD: 2024-03-15
Clinical trial
A Phase II Neoadjuvant Study of the Safety and Tolerability of Anti-PD1 (Nivolumab) Administered Alone or in Combination With Anti-LAG3 (Relatlimab) or Anti-CTLA4 (Ipilimumab) in Resectable Head and Neck CancerStatus: Recruiting, Estimated PCD: 2027-05-31
Clinical trial
Phase 2 Proof of Concept Study of Nivolumab and Ipilimumab in Children and Young Adults With Relapsed or Refractory INI1-negative CancersStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase Ib Study to Evaluate the Safety and Efficacy of Osimertinib in Combination With Ipilimumab in Patients With EGFR Mutated Non-Small-Cell Lung Cancer TumorsStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Clinical trial
Combination Nivolumab and Ipilimumab With and Without Camu Camu in First Line Treatment of Metastatic Renal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2026-03-14
Clinical trial
Multicenter Phase 1b/2 Trial Testing Neoadjuvant Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma - MARIANEStatus: Not yet recruiting, Estimated PCD: 2026-02-01
Clinical trial
A Randomized Phase I/II Study of Neoadjuvant Treatment With 177-Lutetium- PSMA-617 With or Without Ipilimumab in Subjects With Very High-risk Prostate Cancer Who Are Candidates for Radical Prostatectomy (NEPI Trial)Status: Not yet recruiting, Estimated PCD: 2027-03-01
Clinical trial
Ipilimumab Combined With Ibrutinib and Nivolumab for Patients With Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Pilot Integrated Biomarker Study of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Resectable Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2023-12-15
Clinical trial
Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR)Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Randomized Phase I Trial to Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (COSINR Study)Status: Active (not recruiting), Estimated PCD: 2026-12-01
Clinical trial
UPCC06820 Phase 1 Trial of Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected PrimaryStatus: Terminated, Estimated PCD: 2024-01-31
Clinical trial
A Phase II, Single Arm Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase II Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed GlioblastomaStatus: Terminated, Estimated PCD: 2023-05-02
Clinical trial
Bevacizumab and Immune chEckpoint Inhibitors Plus Hypofractionated Stereotactic radioTherapy for the Treatment of sympTomatic mElanoma bRain Metastases.Status: Not yet recruiting, Estimated PCD: 2026-01-30
Clinical trial
Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma: An Open-label GERCOR Phase II StudyStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary TumorsStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients With Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination With Ipilimumab Followed by Nivolumab MonotherapyStatus: Terminated, Estimated PCD: 2020-07-28
Clinical trial
Randomized Phase II Study to Evaluate Induction Nivolumab-Ipilimumab, Followed by Nivolumab With Chemoradiotherapy Versus Chemoradiotherapy for Advanced Cervical CancerStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint BlockadeStatus: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal MelanomaStatus: Completed, Estimated PCD: 2019-12-02
Clinical trial
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab for Patients With Resectable Stage IB - III Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2024-04-15
Clinical trial
Efficacy and Safety Trial of XH001 (Neoantigen Cancer Vaccine) Sequential Combination With Ipilimumab and Chemotherapy for Patients With Resected Pancreatic CancerStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary MelanomaStatus: Active (not recruiting), Estimated PCD: 2022-01-11
Clinical trial
MEL-212: A Phase I Proof-of-Concept Study of CBL0137 (Curaxin) Combined With Ipilimumab and Nivolumab Therapy in Locally Advanced or Metastatic MelanomaStatus: , Estimated PCD: 2025-03-04
Clinical trial
Randomized Phase III Study Comparing a Non-myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Tumor Infiltrating Lymphocytes and Interleukin-2 to Standard Ipilimumab Treatment in Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2022-09-01
Clinical trial
First Line Randomised Study Platform to Optimize Treatment in Patients With Metastatic Renal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2032-05-05
Clinical trial
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)Status: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
Prospective randomIzed Clinical Trial Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma Treated With CTLA-4 and PD1 InhibitorsStatus: Recruiting, Estimated PCD: 2024-01-20
Clinical trial
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase 2 Study of the Safety, Efficacy, and Immune Response of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Patients With Previously Treated Metastatic Pancreatic AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-04-03
Clinical trial
A Pilot Study to Evaluate the Safety of Neoadjuvant Nivolumab Alone or in Combination With Ipilimumab for Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (CA209-9DJ)Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Prospective Randomized, Open-label Phase 2 Study of Immune Checkpoint Inhibition, Nivolumab With or Without Ipilimumab in Combination With Radiation Therapy in Pretreated Patients With Metastatic Pancreatic Cancer or Biliary Tract Cancer.Status: Completed, Estimated PCD: 2022-01-05
Clinical trial
SiCARIO (Split Course Adaptive Radioimmunotherapy) for the Treatment of Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Using Biologically-Adaptive Radiotherapy - A Phase I/II StudyStatus: , Estimated PCD: 2026-02-01
Clinical trial
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Immunotherapy in Patients With Early dMMR Rectal CancerStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic CancersStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Clinical trial
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesStatus: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Phase 2 Study of Axitinib + Ipilimumab in Advanced MelanomaStatus: Recruiting, Estimated PCD: 2024-08-02
Clinical trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III TrialStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Intratumoral Ipilimumab in Head and Neck CancerStatus: Active (not recruiting), Estimated PCD: 2019-09-21
Clinical trial
Phase Ib Study of Cellular Adoptive Immunotherapy Using Autologous Cd8+ Antigen-Specific T Cells and Anti-Ctla4 for Patients With Metastatic Uveal MelanomaStatus: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
Phase II Study of Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable MelanomaStatus: Not yet recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Phase I Study of Nivolumab in Combination With Ipilimumab for the Treatment of Patients With High Risk or Refractory/Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell TransplantationStatus: Active (not recruiting), Estimated PCD: 2026-03-31
Clinical trial
Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma PatientsStatus: Recruiting, Estimated PCD: 2027-01-23
Clinical trial
A Feasibility Study To Determine T-cell Responses To Neoantigens Following Treatment With Ipilimumab In Men With Metastatic Castration-Resistant Prostate CarcinomaStatus: Completed, Estimated PCD: 2019-11-04
Clinical trial
LAPTOP: Phase 1/2 Study in Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer to Assess Safety and Potential Efficacy of Dual Checkpoint Inhibition in Combination With Gemcitabine and Nab-paclitaxel Followed by Immune-chemoradiation.Status: Active (not recruiting), Estimated PCD: 2024-05-24
Clinical trial
Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 AntibodyStatus: Active (not recruiting), Estimated PCD: 2022-06-01
Clinical trial
A Phase II Trial Of Ipilimumab In Combination With Nivolumab In Patients With Advanced Nasopharyngeal CarcinomaStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based AssayStatus: Terminated, Estimated PCD: 2021-06-01
Clinical trial
Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination With Nivolumab/Ipilimumab for Patients With Metastatic Renal Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-06-11
Clinical trial
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 TrialStatus: Not yet recruiting, Estimated PCD: 2026-04-01
Clinical trial
Phase I Integrated Biomarker Trial of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Pancreatic and Colorectal CancerStatus: Completed, Estimated PCD: 2021-10-28
Clinical trial
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With IpilimumabStatus: Completed, Estimated PCD: 2021-09-30
Clinical trial
A Single Arm Phase 2 Study of Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer.Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and IpilimumabStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Pilot Study of a DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable SarcomaStatus: Completed, Estimated PCD: 2019-04-01
Clinical trial
A Pilot Study of Pre-Operative, Single-Dose Ipilimumab, Nivolumab and Cryoablation in Early Stage/Resectable Breast CancerStatus: Completed, Estimated PCD: 2024-06-07
Clinical trial
Phase II Study Investigating the Efficacy of Neoadjuvant Dual Checkpoint Inhibition and Cryoablation Therapy in Children, Adolescents, and Young Adults With Relapsed/Refractory Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
SAINT: A Phase 1/2 Study of Safe Amounts of IPLIMUMAB, NIVOLUMAB and TRABECTEDIN as First Line Treatment of Advanced Soft Tissue Sarcoma (STS)Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase I Clinical Trial on Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent GlioblastomaStatus: , Estimated PCD: 2023-11-17
Clinical trial
Nivolumab (Anti-PD1 Antibody) and Ipilimumab (Anti-CTLA4 Antibody) in Combination With Immunogenic Chemotherapy for Patients With Advanced Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Neoadjuvant Phase IIa Study of Ipilimumab {Formerly Known as MDX-010 (BMS-734016)} Plus Hormone Ablation in Men With Prostate Cancer Followed by Radical Prostatectomy.Status: Completed, Estimated PCD: 2015-10-01
Clinical trial
A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLCStatus: Completed, Estimated PCD: 2022-05-09
Clinical trial
A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cyclophosphamide) in Patients With Previously Treated Metastatic Pancreatic AdenocarcinomaStatus: Completed, Estimated PCD: 2022-08-03
Clinical trial
A Phase 2 Study Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical ProstatectomyStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
Phase 1B Study to Assess Safety and Efficacy of Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (NABUCCO)Status: Completed, Estimated PCD: 2021-07-19
Clinical trial
Pilot Study of NP-101 (TQ Formula) in Combination With Nivolumab and Ipilimumab in Advanced and Metastatic Extra-pulmonary Neuroendocrine Carcinomas (EP-NECAs)Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed MeningiomaStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Adjuvant Nivolumab or Ipilimumab + Nivolumab Determined By Pathological Response To A Single Dose Of Neoadjvuant NivolumabStatus: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
Safety and Efficacy of SRS and Immune Checkpoint Inhibitors (ICI) Concurrent With NovoTTF-100M in Melanoma Brain MetastasesStatus: Recruiting, Estimated PCD: 2025-03-06
Clinical trial
A Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2023-05-22
Clinical trial
DISCERN: Dual Immune Strategy Versus Single Checkpoint Inhibition Efficacy Response in PDL-1 Negative Non-Small Cell Lung Cancer (NSCLC)Status: Not yet recruiting, Estimated PCD: 2027-01-30
Clinical trial
A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase II Trial of Ipilimumab With and Without Nivolumab in Patients With Relapsed/Refractory Classic Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
A Multicenter, Randomised, Open-label Phase II Study to Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2024-03-15
Clinical trial
A Phase II Study of High Dose Bolus IL2 in Combination With Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 ImmunotherapyStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Nivolumab, Ipilimumab and Radiation in Combination With Influenza Vaccine in Patients With Pancreatic Cancer (INFLUENCE)Status: Terminated, Estimated PCD: 2023-10-19
Clinical trial
Phase Ib Study of Copanlisib in Combination With Nivolumab or With Nivolumab and IpilimumabStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase I Study Evaluating Safety and Efficacy of Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2022-11-04
Clinical trial
A Phase 2 Study Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Phase 2 Study of Ipilimumab Plus Nivolumab in Combination With Cryotherapy in Metastatic or Locally Advanced Soft Tissue SarcomaStatus: Completed, Estimated PCD: 2022-01-31
Clinical trial
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 AgentStatus: Active (not recruiting), Estimated PCD: 2023-09-19
Clinical trial
A Phase Ib Clinical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters Following Neoadjuvant Anti-PD-1 (Nivolumab), or the Combination of Anti-PD-1 Plus Anti-CTLA-4 (Nivolumab Plus Ipilimumab) in Patients With Surgically Accessible GlioblastomaStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine CarcinomasStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Efficacy of Immunotherapy in Melanoma Patients With Brain Metastases Treated With SteroidsStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced Or Recurrent Head and Neck Carcinoma. Subtitle: Hypoxia as a Determinant for the Effect of Nivolumab With or Without Ipilimumab on Intra-tumoral T Cell CapacityStatus: Completed, Estimated PCD: 2019-10-12
Clinical trial
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)Status: Recruiting, Estimated PCD: 2028-06-15
Clinical trial
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + BevacizumabStatus: Recruiting, Estimated PCD: 2024-01-31
Clinical trial
A Phase II Study of Open Label Low Dose Ipilimumab in Combination With Pembrolizumab in Metastatic Melanoma Patients With Brain MetastasesStatus: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
A Phase I/II Study of Intratumoral Injection of Ipilimumab in Combination With Local Radiation in Melanoma, Non-Hodkgkin Lymphoma and Colorectal CarcinomaStatus: Terminated, Estimated PCD: 2014-11-01
Clinical trial
Intralesional Influenza Vaccine for Patients With MelanomaStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2026-03-31
Clinical trial
Phase I/II Trial of Ipilimumab or Nivolumab With BMS-986156 and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-08-29
Clinical trial
A Randomized Phase 2 Trial of Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Blinded, Randomized Phase 2 Study of Troriluzole in Combination With Ipilimumab and Nivolumab in Patients With Melanoma Brain Metastases Previously Treated With Anti-PD-1 TherapyStatus: Terminated, Estimated PCD: 2023-05-29
Clinical trial
Phase I/II Intratumoral Administration of Hu14.18-IL2, With Local Radiation, Nivolumab and Ipilimumab in Subjects With Advanced MelanomaStatus: , Estimated PCD: 2024-08-15
Clinical trial
Interest of iRECIST Radiological Assessment for Disease Control Rate (DCR) for Evaluation of Patients With Metastatic Colorectal Cancer dMMR and/or MSI Treated With Nivolumab and Ipilimumab. A GERCOR Open-label Phase II Study NIPICOL C17-01Status: Active (not recruiting), Estimated PCD: 2019-02-21
Clinical trial
Randomized Phase 2 Study of Nivolumab and Ipilimumab With or Without Cabozantinib in Patients With Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and ImmunotherapyStatus: Recruiting, Estimated PCD: 2028-06-16
Clinical trial
An Open-Label Preoperative Pilot Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable (HCC)Status: Completed, Estimated PCD: 2022-09-14
Clinical trial
Phase I/II Study of Ipilimumab Plus Nivolumab (IPI-NIVO) Combined With Sacituzumab Govitecan (SG)as First-line Treatment for Cisplatin-ineligible Metastatic Urothelial CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-10-11
Clinical trial
Phase II Study of Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced MelanomaStatus: , Estimated PCD: 2023-03-03
Clinical trial
Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath TumorStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]Status: Active (not recruiting), Estimated PCD: 2024-09-15
Clinical trial
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV MelanomaStatus: Active (not recruiting), Estimated PCD: 2021-10-06
Clinical trial
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab Versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2022-04-06
Clinical trial
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck CancerStatus: Completed, Estimated PCD: 2016-10-29
Clinical trial
Phase I Multicenter Trial Combining Nivolumab, Alone or With Ipilimumab, Plus Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer PatientsStatus: Terminated, Estimated PCD: 2019-07-02
Clinical trial
An Open-Label Phase II Study of Nivolumab in Adult Participants With Progressive/Recurrent MeningiomaStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Randomized Phase I/II Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic MelanomaStatus: Completed, Estimated PCD: 2021-01-01
Clinical trial
A Phase I/II Trial of Combination Tumor Treating Fields, Nivolumab Plus/Minus Ipilimumab for Recurrent GlioblastomaStatus: Terminated, Estimated PCD: 2020-05-29
Clinical trial
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural MesotheliomaStatus: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
Combination Treatment of Nivolumab, Ipilimumab, Intratumoral CMP-001 and Radiosurgery for Liver Metastases in Colorectal CarcinomaStatus: Completed, Estimated PCD: 2021-08-18
Clinical trial
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or GliosarcomaStatus: Recruiting, Estimated PCD: 2025-11-30